CN115135323A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN115135323A
CN115135323A CN202180015307.7A CN202180015307A CN115135323A CN 115135323 A CN115135323 A CN 115135323A CN 202180015307 A CN202180015307 A CN 202180015307A CN 115135323 A CN115135323 A CN 115135323A
Authority
CN
China
Prior art keywords
pharmaceutical composition
certain embodiments
total weight
amount
api
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180015307.7A
Other languages
English (en)
Chinese (zh)
Inventor
王泽人
徐俊
彼得·法里纳
陈顺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Pharmacin Co Ltd
Original Assignee
Shenzhen Pharmacin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Pharmacin Co Ltd filed Critical Shenzhen Pharmacin Co Ltd
Publication of CN115135323A publication Critical patent/CN115135323A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180015307.7A 2020-04-17 2021-04-16 药物组合物 Pending CN115135323A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/085241 2020-04-17
CN2020085241 2020-04-17
PCT/CN2021/087690 WO2021209025A1 (en) 2020-04-17 2021-04-16 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN115135323A true CN115135323A (zh) 2022-09-30

Family

ID=78084668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180015307.7A Pending CN115135323A (zh) 2020-04-17 2021-04-16 药物组合物

Country Status (8)

Country Link
US (1) US20230128252A1 (https=)
EP (1) EP4135699A4 (https=)
JP (1) JP2023522065A (https=)
KR (1) KR20230004644A (https=)
CN (1) CN115135323A (https=)
AU (1) AU2021255559A1 (https=)
CA (1) CA3180160A1 (https=)
WO (1) WO2021209025A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116115563A (zh) * 2023-03-30 2023-05-16 石家庄四药有限公司 一种氟比洛芬混悬注射液及其制备方法
CN117731649A (zh) * 2023-12-21 2024-03-22 博济医药科技股份有限公司 一种氨甲环酸药物组合物及其制备工艺
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions
CN119837856A (zh) * 2024-12-11 2025-04-18 江南大学 一种具有预防和改善特应性皮炎的黄酮组合物及其应用
CN120865107A (zh) * 2025-09-22 2025-10-31 中国医学科学院医药生物技术研究所 一种苯吩嗪衍生物、其制备方法与用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059475A1 (en) * 1999-04-06 2000-10-12 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20070269393A1 (en) * 1999-10-22 2007-11-22 Scott Wepfer Topical anesthetic formulation
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
WO2014074289A1 (en) * 2012-11-06 2014-05-15 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
CN104582734A (zh) * 2012-05-02 2015-04-29 萨米·萨阿德 局部非水性药物配制剂
CN105492004A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗局部微生物感染的方法
CN105693668A (zh) * 2016-04-23 2016-06-22 贺玉皓 一种氯法齐明的药物组合物及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814814C2 (de) * 1998-04-02 2002-01-31 Gerhard Steffan Wasserlösliche, Iminophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059475A1 (en) * 1999-04-06 2000-10-12 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20070269393A1 (en) * 1999-10-22 2007-11-22 Scott Wepfer Topical anesthetic formulation
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
CN104582734A (zh) * 2012-05-02 2015-04-29 萨米·萨阿德 局部非水性药物配制剂
WO2014074289A1 (en) * 2012-11-06 2014-05-15 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
CN105492004A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗局部微生物感染的方法
CN105693668A (zh) * 2016-04-23 2016-06-22 贺玉皓 一种氯法齐明的药物组合物及其医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORNEL B等: "Formulation of Natural Oil Nano-Emulsions for the Topical Delivery of Clofazimine , Artemisone and Decoquinate", PHARMACEUTICAL RESEARCH, vol. 35, no. 10, 7 August 2018 (2018-08-07), XP036589039, DOI: 10.1007/s11095-018-2471-9 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116115563A (zh) * 2023-03-30 2023-05-16 石家庄四药有限公司 一种氟比洛芬混悬注射液及其制备方法
CN116115563B (zh) * 2023-03-30 2023-08-29 石家庄四药有限公司 一种氟比洛芬混悬注射液及其制备方法
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions
CN117731649A (zh) * 2023-12-21 2024-03-22 博济医药科技股份有限公司 一种氨甲环酸药物组合物及其制备工艺
CN119837856A (zh) * 2024-12-11 2025-04-18 江南大学 一种具有预防和改善特应性皮炎的黄酮组合物及其应用
CN120865107A (zh) * 2025-09-22 2025-10-31 中国医学科学院医药生物技术研究所 一种苯吩嗪衍生物、其制备方法与用途

Also Published As

Publication number Publication date
WO2021209025A1 (en) 2021-10-21
AU2021255559A1 (en) 2022-11-17
JP2023522065A (ja) 2023-05-26
US20230128252A1 (en) 2023-04-27
EP4135699A4 (en) 2024-05-01
EP4135699A1 (en) 2023-02-22
KR20230004644A (ko) 2023-01-06
CA3180160A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
CN115135323A (zh) 药物组合物
US9415108B2 (en) Compositions for transdermal delivery of active agents
EP2191828B1 (en) Antifungal pharmaceutical composition
EP1962817B1 (en) Transdermal delivery of a salt form of meptazinol
EP2266626B1 (en) Composition for external application comprising transcription factor decoy as active ingredient
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
KR20150104102A (ko) 테트라사이클린 국소 제제, 제조방법, 및 이의 용도
CN102196821A (zh) 包含至少两种渗透增强剂组合的局部组合物
WO2009081217A1 (en) Pharmaceutical formulations containing tolperisone
KR20130128375A (ko) 피부 질환을 치료 또는 예방하기 위한 화합물들의 배합물
KR20120118495A (ko) 국부 마취제 에멀전 조성물 및 이의 제조 및 사용 방법
US9427435B2 (en) Narcotic emulsion formulations for treatment of cancer pain
TWI729371B (zh) 治療搔癢症的組合物與方法
AU2022399851A1 (en) Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
WO2023102559A1 (en) Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
CN110402142A (zh) 含局麻药的酸性乳液组合物
US20050158371A1 (en) Novel external agent
WO2015181746A1 (en) Gel form of a heparin sodium salt for dermal administration, and a method for its preparation.
JP6131523B2 (ja) ロキソプロフェン含有外用剤
JP6625208B2 (ja) 経皮製剤
JP2775053B2 (ja) モルフィン類を含有する外用製剤
JP2013087067A (ja) ローション剤
WO2016052617A1 (ja) ナルフラフィン含有局所適用製剤
CN115279788A (zh) 用于治疗银屑病和其他疾病的外用环孢霉素
JP2009007265A (ja) 表在性真菌症予防および治療用非経口投与剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220930